<DOC>
	<DOCNO>NCT00864331</DOCNO>
	<brief_summary>Primary objective study : To assess difference survival two treatment option stage III ( A B ) nonsmall cell lung cancer ( NSCLC ) ( Study A ) Stage IIIB ( wet ) stage IV NSCLC ( Study B ) , respectively Secondary objective : To assess difference toxicity two treatment option stage III ( A B ) NSCLC ( Study A ) Stage IIIB ( wet ) stage IV NSCLC ( Study B ) , To assess difference Health Related Quality Life ( HRQoL ) two treatment option Study A Study B</brief_summary>
	<brief_title>Optimization Treatment Advanced Nonsmall Cell Lung Cancer Using Radiotherapy Chemotherapy</brief_title>
	<detailed_description>To compare survival rate ( median 1-year ) , toxicity two treatment regimen patient locally advance incurable NSCLC ( study A ) , compare survival rate ( median 1-year ) two treatment regimen patient locally advance metastatic NSCLC ( study B ) To compare HRQoL cost effectiveness two treatment regimen patient locally advance incurable NSCLC ( study A ) , patient locally advance metastatic NSCLC ( study B ) evaluate effect HRQoL assessment QoL dimension</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Study A Histologically cytologically confirm NSCLC Stage IIIA/IIIB stag CT chest upper abdomen Liver , renal , hematological reserve appropriate ( accord `` standard '' institutional value ) Brain CT and/or bone scan clinical symptom request investigation Performance status KPS 6090 No second cancer except skin nonmelanoma No previous treatment Patient must contactable followup Patient able start treatment within 2 week randomization ( institutional confirmation need ) Life expectancy &gt; 3 month Patient must able willing give inform consent , fill questionnaire Study A Stage III B `` wet '' ( exist pleural effusion , necessarily cytologically verify ) RT field &gt; 200 cm2 Pregnancy Study B KPS 6090 Stage IV Stage III B ( exist pleural effusion , necessarily cytologically verify ) Histologically cytologically confirm CT stag disease ( thorax possible upper abdomen ) No second cancer except skin nonmelanoma Liver , renal , haematological reserve appropriate ( accord `` standard '' institutional value ) No previous treatment Patient must contactable followup Patient must able willing give inform consent fill questionnaires Patient able start treatment within 2 week randomization ( institutional confirmation need ) Life expectancy &gt; 3 month Study B Brain metastasis ( brain CT and/or MRI need , unless symptom exist clinically indicate ) RT field &gt; 200 cm2 Pregnancy AP separation large adequately treat 60Co ( ? )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>nonsmall cell lung cancer</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>Locally advanced metastatic nonsmall cell lung cancer</keyword>
</DOC>